Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate (FF); ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone650-238-9600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$261 million
Profitability
Miscellaneous
Employees6
Next Earnings Date4/25/2019 (Estimated)
OptionableOptionable
Innoviva (NASDAQ:INVA) Frequently Asked Questions
What is Innoviva's stock symbol?
Innoviva trades on the NASDAQ under the ticker symbol "INVA."
How were Innoviva's earnings last quarter?
Innoviva Inc (NASDAQ:INVA) posted its earnings results on Wednesday, February, 6th. The biotechnology company reported $2.34 earnings per share for the quarter. The biotechnology company earned $79.86 million during the quarter. Innoviva had a negative return on equity of 508.18% and a net margin of 151.36%. View Innoviva's Earnings History.
When is Innoviva's next earnings date?
What price target have analysts set for INVA?
1 Wall Street analysts have issued twelve-month price objectives for Innoviva's shares. Their predictions range from $16.00 to $16.00. On average, they anticipate Innoviva's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 22.1% from the stock's current price. View Analyst Price Targets for Innoviva.
What is the consensus analysts' recommendation for Innoviva?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Innoviva.
Has Innoviva been receiving favorable news coverage?
News headlines about INVA stock have been trending somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Innoviva earned a daily sentiment score of 1.2 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.
Are investors shorting Innoviva?
Innoviva saw a decrease in short interest in the month of March. As of March 15th, there was short interest totalling 16,588,540 shares, a decrease of 10.7% from the February 28th total of 18,584,058 shares. Based on an average daily trading volume, of 936,628 shares, the short-interest ratio is presently 17.7 days. Currently, 25.0% of the shares of the stock are short sold. View Innoviva's Current Options Chain.
Who are some of Innoviva's key competitors?
Some companies that are related to Innoviva include Alkermes (ALKS), Patheon (PTHN), Array Biopharma (ARRY), GW Pharmaceuticals PLC- (GWPH), Horizon Pharma (HZNP), Ascendis Pharma A/S (ASND), United Therapeutics (UTHR), TESARO (TSRO), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), FibroGen (FGEN), Evotec (EVTCY), Amneal Pharmaceuticals (AMRX), ACADIA Pharmaceuticals (ACAD) and Ultragenyx Pharmaceutical (RARE).
What other stocks do shareholders of Innoviva own?
Who are Innoviva's key executives?
Innoviva's management team includes the folowing people:
- Mr. Geoffrey Hulme, Interim Principal Exec. Officer (Age 52)
- Ms. Marianne Zhen CPA, Chief Accounting Officer (Age 50)
- Mr. Jeffrey A. Hagenah Ph.D., Chief Patent Counsel and VP
- Dr. Kevin Kwok, Head of Talent Acquisition & Strategy
Who are Innoviva's major shareholders?
Innoviva's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Aurora Investment Counsel (0.08%), Nisa Investment Advisors LLC (0.03%), Alpha Windward LLC (0.03%), First Hawaiian Bank (0.03%), Tibra Equities Europe Ltd (0.03%) and Meeder Asset Management Inc. (0.01%). Company insiders that own Innoviva stock include Eric Desparbes, Geoffrey Hulme, George B Abercrombie, George Bickerstaff, Marianne Zhen, Michael W Aguiar and Theodore J Jr Witek. View Institutional Ownership Trends for Innoviva.
Which major investors are selling Innoviva stock?
INVA stock was sold by a variety of institutional investors in the last quarter, including Toth Financial Advisory Corp, Aurora Investment Counsel and 6 Meridian. Company insiders that have sold Innoviva company stock in the last year include Eric Desparbes, George B Abercrombie, Marianne Zhen and Theodore J Jr Witek. View Insider Buying and Selling for Innoviva.
Which major investors are buying Innoviva stock?
INVA stock was purchased by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Tibra Equities Europe Ltd, Meeder Asset Management Inc., First Hawaiian Bank and Alpha Windward LLC. Company insiders that have bought Innoviva stock in the last two years include Geoffrey Hulme and George Bickerstaff. View Insider Buying and Selling for Innoviva.
How do I buy shares of Innoviva?
Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innoviva's stock price today?
One share of INVA stock can currently be purchased for approximately $13.10.
How big of a company is Innoviva?
Innoviva has a market capitalization of $1.32 billion and generates $261 million in revenue each year. The biotechnology company earns $395.05 million in net income (profit) each year or $3.53 on an earnings per share basis. Innoviva employs 6 workers across the globe.
What is Innoviva's official website?
How can I contact Innoviva?
Innoviva's mailing address is 2000 SIERRA POINT PARKWAY SUITE 500, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]
MarketBeat Community Rating for Innoviva (NASDAQ INVA)
MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe INVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
